Get the Stockscreener App
1.5845
0.30%
0.0555
Alx Oncology Holdings Inc stock is traded at $1.5845, with a volume of 85,091.
It is up +0.30% in the last 24 hours and up +55.19% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.64
Open:
$1.7
24h Volume:
85,091
Relative Volume:
0.09
Market Cap:
$85.79M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.5335
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-22.04%
1M Performance:
+55.19%
6M Performance:
+235.71%
1Y Performance:
+6.82%
1-Day Range:
$1.602
$1.738
1-Week Range:
$1.61
$2.14
52-Week Range:
$0.404
$2.27
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.602 | 87.82M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
Real time breakdown of ALX Oncology Holdings Inc. stock performanceCEO Change & High Return Trade Opportunity Guides - newser.com
Relative strength of ALX Oncology Holdings Inc. in sector analysisJuly 2025 Spike Watch & Capital Protection Trading Alerts - newser.com
Is ALX Oncology Holdings Inc a good long term investmentMoving Average Crossovers & Free High Yield Market Plays - earlytimes.in
Chart based analysis of ALX Oncology Holdings Inc. trendsMarket Activity Recap & Entry Point Confirmation Alerts - newser.com
ALX Oncology (NASDAQ:ALXO) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
How moving averages guide ALX Oncology Holdings Inc. trading2025 EndofYear Setup & Low Risk High Reward Ideas - newser.com
Is ALX Oncology Holdings Inc. still worth holding after the dipJuly 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 - GlobeNewswire
ALX Oncology to present CD47 biomarker data for evorpacept at SITC - Investing.com Nigeria
Upcoming Events - FinancialContent
ALX Oncology Holdings Inc Stock Analysis and ForecastGrowth vs. Value Investing & Exceptional Return Investment - earlytimes.in
Revolution Medicines hires Mirati, ALX vet Sandler - biocentury.com
ALX Oncology Holdings (ALXO) Price Target Increased by 18.52% to 2.72 - Nasdaq
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer - GlobeNewswire Inc.
Goldman Sachs Group Inc. Sells 195,795 Shares of ALX Oncology Holdings Inc. $ALXO - Defense World
Pan India Corporation Limited Earnings Review What Investors Need to KnowGrowth vs. Value Investing & Interactive Charts for Smarter Trading - earlytimes.in
What analysts say about ALX Oncology Holdings Inc stockMean Reversion Trades & Big Gains Small Investment - earlytimes.in
ALX Oncology Holdings Inc. stock retracement – recovery analysisEarnings Growth Report & High Return Stock Watch Alerts - newser.com
What to do if you’re stuck in ALX Oncology Holdings Inc.July 2025 Rallies & High Yield Stock Recommendations - newser.com
3 Promising Penny Stocks With Market Caps Under $700M - Yahoo Finance
What earnings revisions data tells us about ALX Oncology Holdings Inc.2025 Investor Takeaways & Daily Price Action Insights - newser.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Buys 21,070 Shares - MarketBeat
Is now a turning point for ALX Oncology Holdings Inc.July 2025 Opening Moves & Verified Chart Pattern Signals - newser.com
ALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Buys 71,163 Shares - MarketBeat
CEO & Director of ALX Oncology Holdings Picks Up 69% More Stock - Yahoo Finance
Trend Recap: Is SYTA backed by strong institutional buyingJuly 2025 Rallies & Free Accurate Trade Setup Notifications - خودرو بانک
Portfolio Update: How volatile is ALX Oncology Holdings Inc stockJuly 2025 Drop Watch & AI Based Trade Execution Alerts - khodrobank.com
Will ALX Oncology Holdings Inc. rebound enough to break evenMarket Movers & Fast Exit Strategy with Risk Control - newser.com
Volatility Watch: Will ALX Oncology Holdings Inc. outperform tech stocksRate Hike & Stepwise Trade Execution Plans - khodrobank.com
Day Trade: Can ALX Oncology Holdings Inc beat the S P 5002025 Year in Review & Fast Gaining Stock Reports - khodrobank.com
Can technical indicators confirm ALX Oncology Holdings Inc.’s reversalQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
Chipmakers Recap: Will ALX Oncology Holdings Inc stock hit new highs in YEARJuly 2025 Action & Accurate Intraday Trade Tips - خودرو بانک
Evaluating ALX Oncology Holdings Inc. with trendline analysis - newser.com
Pharma News: Does ALX Oncology Holdings Inc have strong EBITDA margins2025 Support & Resistance & Risk Controlled Stock Pick Alerts - khodrobank.com
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):